Ethylene Oxide (EO) Sterilization Residue Determination for Medical Devices: Standards, Methods, and

Ethylene oxide (EO) sterilization residue determination is a critical safety evaluation for medical devices sterilized with EO, verifying that residual ethylene oxide (EO) and ethylene chlorohydrin (ECH) remain below the allowable limits specified in ISO 10993-7 before products are released to market. This article explains the regulatory basis, residue limits, sample types, analytical methods, and practical requirements for EO residue testing performed by accredited third-party laboratories and in-house facilities.

Technical Overview

Ethylene oxide sterilization is one of the most widely used low-temperature sterilization processes for medical devices that are sensitive to heat and moisture, with the sterilization process itself validated according to ISO 11135. Because EO is a reactive alkylating agent with documented toxicity, irritancy, and carcinogenicity concerns, residues of EO and its reaction by-products—primarily ethylene chlorohydrin (ECH, 2-chloroethanol) and ethylene glycol (EG)—can remain adsorbed in polymers, cellulose-based materials, and packaging after sterilization. EO sterilization residue determination is the analytical process of extracting and quantifying these residuals and comparing them against biologically based allowable limits.

The governing international standard is ISO 10993-7 (Biological evaluation of medical devices — Part 7: Ethylene oxide sterilization residuals), which is harmonized in China as GB/T 16886.7 and adopted in Europe as EN ISO 10993-7. The standard defines patient-exposure duration categories and corresponding maximum allowable residue levels. Representative limits per device include:

• EO: up to 4 mg per device for limited-exposure devices (patient contact ≤ 24 hours) and up to 2 mg for prolonged-exposure devices (24 hours to 30 days).
• ECH: up to 5 mg per device for limited- and prolonged-exposure categories, with lower values applying to long-term contact devices.
• Special reduced limits apply to specific device types, such as intraocular lenses (covered by ISO 11979-5) and blood-contacting extracorporeal devices.

Because actual limits depend on device category, patient population, and contact duration, manufacturers must evaluate their specific product configuration against the full limit tables in ISO 10993-7 and document the scientific justification for the applicable limit.

Testing Samples

EO residue testing is applicable to any medical device, component, or material that has been exposed to ethylene oxide sterilization. Typical sample categories include:

Single-Use Sterile Devices

Syringes, hypodermic needles, intravenous cannulas, infusion and transfusion sets, urinary catheters, central venous catheters, breathing circuits, anesthesia masks, drainage sets, and blood collection tubes. These polymer-heavy constructions tend to adsorb EO strongly and represent the largest testing volume.

Surgical Products and Implants

Absorbable and non-absorbable sutures, hernia meshes, ligature clips, wound dressings, absorbable hemostatic materials, tape products, and packaging components in direct contact with the device. Cellulose and porous materials generally retain more EO and require longer aeration.

Extracorporeal and High-Risk Devices

Hemodialyzers, blood oxygenators, extracorporeal tubing sets, and cardiopulmonary bypass circuits, where large surface areas and blood contact can result in higher patient exposure and therefore stricter evaluation requirements.

Electronic and Diagnostic Devices

Battery-powered surgical instruments, endoscopic components, sensors, in vitro diagnostic consumables, and lab plasticware that cannot withstand steam or radiation sterilization.

For all sample types, correct handling is essential: samples must be sealed immediately after the aeration phase in gas-tight containers (such as foil-lined laminate bags or sealed headspace vials) with minimal headspace, and analyzed as soon as practicable to prevent EO loss through volatilization.

Testing Items

A complete EO residue evaluation program typically includes the following determinations:

• EO residue content: quantified in mg per device (or µg per gram of material) and compared with the applicable ISO 10993-7 limit.
• ECH residue content: required when the device contains chlorinated polymers or materials capable of forming ECH, and routinely included in most test reports.
• EG residue content: usually evaluated only when specifically relevant to the product construction or requested by a regulator.
• Aeration dissipation study: measurement of residue levels at multiple time points after sterilization to establish an aeration curve and define the minimum aeration time for routine release.
• Product family evaluation: justification that one representative configuration covers the worst-case residue behavior of the family, based on material, mass, and surface area.

Testing Methods

ISO 10993-7 defines both the extraction philosophy and the analytical approach. Testing is performed using gas chromatography-based methods, and quantitative work should be carried out in ISO/IEC 17025 accredited third-party laboratories or validated in-house facilities.

Sample Preparation and Extraction

Two extraction concepts are used, selected according to how the device contacts the patient:

• Simulated-use extraction: the device is extracted in water under conditions that simulate clinical use (commonly 37 °C for 24 hours, or the actual use temperature and duration), and the extract reflects the dose a patient would actually receive. This is the preferred approach for devices with fluid pathways or patient-fluid contact.
• Exhaustive extraction: repeated extractions are performed until the residue in each successive extract falls below a defined percentage of the first, providing a conservative total residue value. This approach is applied where simulated use cannot be defined or for regulatory submission purposes.

Instrumental Analysis

• Headspace gas chromatography with flame ionization detection (HS-GC-FID) is the standard technique for EO, exploiting its volatility. Sample portions are sealed in headspace vials and equilibrated at an elevated temperature before automated injection.
• ECH is non-volatile relative to EO and is typically determined by GC-FID or GC-MS following aqueous extraction, using liquid injection or headspace techniques with appropriate sample preparation.
• Calibration is performed with certified reference standards, and an internal standard is commonly used to correct for injection variability. GC-MS confirmation may be employed where specificity is required.

Method Validation and Quality Control

Validated methods must demonstrate linearity across the working range, acceptable recovery from the device matrix, defined limits of detection and quantification (typically well below 1 µg/mL in the extract, corresponding to residue levels far below the allowable limits), and acceptable repeatability. Replicate devices per time point (commonly three to five) are analyzed, and results are converted to mg per device or daily patient dose for comparison against the ISO 10993-7 limits.

Result Evaluation

The reported residue values are compared with the allowable limit for the device's exposure-duration category. Where a device is used on multiple days, the total dose over the evaluation period is considered. If residues exceed the limits, aeration time, sterilizer loading configuration, packaging permeability, or material selection must be modified and re-verified.

Applications

EO sterilization residue determination supports manufacturers at multiple stages of the product lifecycle:

• Regulatory submissions: residue test reports are a mandatory element of premarket documentation such as 510(k) notifications, CE technical files under the EU Medical Device Regulation, and NMPA registration dossiers in China.
• Sterilization validation: residue data confirm the effectiveness of the aeration phase defined during ISO 11135 process validation, including worst-case load configurations.
• Routine product release: periodic residue testing supports ongoing conformity and statistical release criteria for sterilized batches.
• Product and process development: residue profiles guide material selection, packaging design, and aeration optimization, reducing cycle time while maintaining compliance.
• Change control and complaint investigation: retesting is required after changes to materials, suppliers, packaging, or the sterilization cycle, and supports investigation of adverse event reports related to sterilization residuals.

FAQ

Which residues must be measured after EO sterilization?

EO is always measured. ECH must be measured when the device construction can generate it or when required by the applicable standard or regulator; in practice, most test programs include both EO and ECH. EG is included only where specifically justified or requested.

When should samples be taken for residue testing?

For routine release, samples are taken at the earliest point at which the product could be shipped—typically immediately at the end of the validated aeration time. During initial validation, sampling at several time points after sterilization generates the aeration dissipation curve used to set that release point.

How many samples are required?

Typical practice is three to five devices per time point, sampled from worst-case pallet or load positions identified during sterilization validation. The exact number should be defined in the study protocol based on statistical and regulatory considerations.

How should samples be shipped to the laboratory?

Immediately after sampling, devices must be sealed in gas-tight, low-permeability containers with minimal headspace, protected from temperature extremes, and shipped by the fastest available method. Delays and permeable packaging can cause significant EO loss and falsely low results.

What happens if residue levels exceed the limits?

The product cannot be released. The manufacturer must extend aeration, adjust load configuration or packaging, or modify materials, and then re-verify residues through additional testing before release. Root cause analysis and corrective action documentation are expected by auditors and regulators.

How often must EO residue testing be repeated?

Full residue studies are performed during initial sterilization validation. Thereafter, routine testing is conducted at a defined frequency justified by the manufacturer, and re-validation is triggered by changes to the product, packaging, load configuration, or sterilization process.